Lightnews — Scholar-powered news

HemaSphere Journal @hemasphere-journal.bsky.social · 13h

This recent paper reports that children w/ T-cell acute lymphoblastic leukemia in the AIEOP-BFM ALL 2009 trial had favorable outcomes Authors highlight that early MRD levels, CNS involvement and prednisone response are important for risk assessment & treatment decisions👉https://f.mtr.cool/prwuxdtqpi

HemaSphere Journal @hemasphere-journal.bsky.social · 1d

This Editorial highlights how collaboration & mutual support between researchers helped advance understanding of CLL biology, leading to better prognostic tools & therapies Relationships & perseverance are vital in scientific progress, hidden skills not often discussed.👉https://f.mtr.cool/javkjisskd

1

HemaSphere Journal @hemasphere-journal.bsky.social · 1d

Our September issue is now complete! Find the latest #hematology research, always open access 🔓https://f.mtr.cool/rtfwnsvcqm

1

HemaSphere Journal @hemasphere-journal.bsky.social · 2d

This study underscores the pronounced elevation of HO-1 levels in pediatric SCD patients, indicating its potential protective role against heme-induced toxicity during childhood. This finding emphasizes the importance of monitoring and managing HO-1 levels in young patients👉https://bit.ly/3IbvCSD

HemaSphere Journal @hemasphere-journal.bsky.social · 2d

🎙️New Podcast Episode!

Join host HemaSphere Scientific Editor Dr Charles de Bock as he chats with Dr Kai Rejeski. The conversation delves into the complexities of CAR-T therapy, particularly focusing on the associated toxicities & the need for a structured grading system. 👉https://bit.ly/46xKjZA

1

HemaSphere Journal @hemasphere-journal.bsky.social · 4d

🐾 Happy World Animal Day (Dierendag)! 🐶🐱🐰🐦🐢

Celebrate the love & joy our furry, feathered, and scaly friends bring into our lives! Our pets help us while we review, edit, write & publish, & at least here at HemaSphere often join Zoom calls.

📸 Share your cutest pet photos below. #Dierendag2025.

HemaSphere Journal @hemasphere-journal.bsky.social · 6d

Gamma delta (γδ) T cells are pivotal in tumor immunosurveillance & are enriched in epithelial tissues This comprehensive review provides an overview of the rationale for γδ T-cell therapy, ongoing clinical trials, challenges & future role of γδ T-cell-based immune therapies👉https://bit.ly/4lpdYYZ

1

HemaSphere Journal @hemasphere-journal.bsky.social · 7d

Arsenic trioxide reprograms bone marrow microenvironment to eliminate #MRD in #AML, an old dog learns new tricks.

Read more in our recent issue👉https://f.mtr.cool/syqiavxbqd

2

HemaSphere Journal @hemasphere-journal.bsky.social · 8d

These Guidelines on behalf of the European Myeloma Network on VTE prevention & treatment in #MM pts offer evidence-based recommendations. Implementing these guidelines can enhance clinical outcomes and quality of life by reducing morbidity, mortality & treatment interruptions👉https://bit.ly/46kp0uk

2

HemaSphere Journal @hemasphere-journal.bsky.social · 9d

Chronic lymphocytic leukemia (CLL) cells reprogram their tumor microenvironment to promote drug resistance and tumor progression. Targeting the AP-1 transcription factor and stromal compartment may offer new treatment strategies.

👉https://f.mtr.cool/ofxyxakidb

1

HemaSphere Journal @hemasphere-journal.bsky.social · 11d

Arsenic trioxide reprograms bone marrow microenvironment to eliminate #MRD in #AML, an old dog learns new tricks.

Read more in our recent issue👉https://f.mtr.cool/jvybvprmlv

HemaSphere Journal @hemasphere-journal.bsky.social · 12d

The novel B-CAP regimen has proven to be a feasible and effective first-line treatment for older patients with advanced-stage classic #HL. It results in high response rates, favorable 3-year PFS, and sustained improvement in health-related QOL.
👉https://f.mtr.cool/uondeedlhy

HemaSphere Journal @hemasphere-journal.bsky.social · 13d

Authors evaluated real-world outcomes of auto-HCT in 130 adult #NKTCL patients across Asia and Europe. Findings suggest that auto-HCT may be a viable treatment option for selected high-risk patients, especially those in complete remission with undetectable EBV-DNA👉https://f.mtr.cool/icmvhpqdkj

HemaSphere Journal @hemasphere-journal.bsky.social · 16d

Researchers have identified syntenin as a key regulator in the communication between #BMSC and #MM cells. Authors in this recent article show that targeting syntenin can disrupt this crosstalk, enhancing the effectiveness of bortezomib therapy & potentially improving outcomes👉https://bit.ly/4fCuhAg

HemaSphere Journal @hemasphere-journal.bsky.social · 19d

Podcast Replay! 🚨

Dr Adrián Mosquera-Orgueira & Dr Juan Carlos Hernández-Boluda, co-authors of "Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis", discuss the findings & challenges w/ Dr Stephen Hibbs 👉

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mo...

f.mtr.cool

1

Reposted by HemaSphere Journal

Jan Cools @jancools.bsky.social · 20d

Looking forward to this exciting meeting and to represent @hemasphere-journal.bsky.social in this session!

NDLR_conference @ndlrconference.bsky.social · 23d

We are excited to announce our new #NDLR2026 Meet-the-Editor session, with Editors-in-Chief, Prof Andrew Roberts, @bloodjournals.hematology.org and Prof @jancools.bsky.social, @hemasphere-journal.bsky.social who will share their invaluable insights on #publishing in high-impact #hematology journals.

1 2

HemaSphere Journal @hemasphere-journal.bsky.social · 20d

HemaTopics are HemaSphere publications focusing on 🔥 hematology topics. This week we focus on the latest HemaTopic by Scientific Editor C de Bock, which discusses the discovery of targeting NPM1 as a new therapeutic target for AML immunotherapy.

👉https://f.mtr.cool/dlbgueeraz

HemaSphere Journal @hemasphere-journal.bsky.social · 21d

📰This exciting Review Article highlights the emerging role of inflammation in the pathogenesis of acute myeloid leukemia (AML). Understanding inflammatory processes in AML could guide therapeutic strategies, especially for elderly patients where outcomes remain poor.👉https://bit.ly/3HbJzzt

HemaSphere Journal @hemasphere-journal.bsky.social · 22d

Authors of this study present the first humanized MPN xenograft model, demonstrating that PV and ET MSCs can sustain both healthy and MPN-associated hematopoiesis. This model offers valuable insights into the interaction between human BM MSCs and JAK2 V617F mutant clones.

👉

Mesenchymal stromal cells from JAK2V617F myeloproliferative neoplasms support healthy and malignant hematopoiesis in a humanized scaffold model in vivo

Myeloproliferative Neoplasms (MPN) are malignancies of hematopoietic stem and progenitor cells (HSPCs) that lead to the overproduction of mature blood cells. These disorders include Essential Thrombo...

f.mtr.cool

2

Reposted by HemaSphere Journal

NDLR_conference @ndlrconference.bsky.social · 23d

We are excited to announce our new #NDLR2026 Meet-the-Editor session, with Editors-in-Chief, Prof Andrew Roberts, @bloodjournals.hematology.org and Prof @jancools.bsky.social, @hemasphere-journal.bsky.social who will share their invaluable insights on #publishing in high-impact #hematology journals.

4 7

HemaSphere Journal @hemasphere-journal.bsky.social · 26d

🎧 Replay!

Authors of this paper discovered a high-risk subgroup of ped T-LBL, defined by NOTCH1 gene fusions. Prof Roland Kuipers & Dr Jan Loeffen discuss their findings w/ Dr Charles de Bock.

"NOTCH1 fusions in T‐LBL" is on our website & major podcast platforms https://bit.ly/3NhzIHE

HemaSphere Journal @hemasphere-journal.bsky.social · 27d

📰
This Editorial, based on a recent HemaSphere article, https://bit.ly/44Kz3bx , highlights the importance of integrating PD-1 blockade into salvage regimens for patients with #RR cHL who have not had prior PD-1 blockade exposure.

👉https://bit.ly/44Kz3bx

HemaSphere Journal @hemasphere-journal.bsky.social · 29d

🔬 Dive into the latest research with @Hemasphere_EHA! Our open access articles provide ground-breaking insights into #hematology. Stay ahead in your field and collaborate with peers. Our latest issue in progress can always be found here 👉 http://bit.ly/3GIlBvj

#Research #OpenAccess

HemaSphere: Vol 9, No 9

Click on the title to browse this issue

bit.ly

HemaSphere Journal @hemasphere-journal.bsky.social · Sep 8

The combination of eprenetapopt and azacitidine shows promise in treating higher-risk myelodysplastic syndromes and oligoblastic #AML with TP53 mutations. The treatment is well-tolerated and demonstrates significant response rates and improved OS.

Read more here👉https://bit.ly/4lrlMu1
#openaccess

HemaSphere Journal @hemasphere-journal.bsky.social · Sep 5

🎙️New Episode!

Dr Charles de Bock hosts Prof Michel Zwaan and Prof Olaf Heidenreich, two co-authors from the 2025 HemaSphere Award - Top Cited: Biology paper "The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML." 🎧 https://bit.ly/3HJbmr6

1